Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of LP-003 injection in moderate to severe seasonal allergic rhinitis inadequately controlled by standard therapy
CTR20241964Phase 3Completed
- Sponsor
- LongBio Pharma
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of LP-003 in seasonal allergic rhinitis (SAR), sponsored by LongBio Pharma. Started Aug 2024; status: completed.
02
Drugs
LP-003
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20241964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241964.